Gasdermin D N-terminal fragment (GSDMD-N)

The Gasdermin D N-terminal fragment (GSDMD-N) is the pore-forming, biologically active domain released via cleavage of full-length Gasdermin D by inflammatory caspases (caspase-1, -4, -5, -11) during inflammasome activation[1][2][4]. Upon release from autoinhibition, GSDMD-N translocates to the inner leaflet of the plasma membrane, where it oligomerizes and forms large pores (10–15 nm), driving cell lysis and a form of programmed cell death known as pyroptosis. Through these pores, mature pro-inflammatory cytokines such as IL-1β and IL-18 are released, and the cell undergoes a lytic death that contributes to both host antimicrobial defense and inflammatory pathology[1][2][3][6]. GSDMD-N can also act extracellularly to directly kill bacteria. Its activity is essential for innate immune responses, but dysregulated activation or impaired clearance has been implicated in autoinflammatory and infectious diseases, and potentially in tumor immunity[4][6][7]. GSDMD-N, being a protein fragment rather than a standalone gene product, is not typically referred to as a discrete therapeutic target, but its formation is a vital event in the process and is targeted by inhibitors seeking to modulate pyroptosis. Note: "GSDMD-N expression" by itself is not a standard molecular target; the target is more accurately the N-terminal fragment of Gasdermin D (GSDMD-N), which arises by proteolytic cleavage and is not independently encoded or transcribed. All therapeutically relevant interventions act by either blocking generation or function of GSDMD-N[1][2][3].

Other names

Gasdermin D active N-terminalGSDMD active N-termGSDMD-N fragmentActive GSDMD

Drugs that inhibit caspase-1, caspase-4, caspase-5, or caspase-11 prevent GSDMD cleavage and, consequently, GSDMD-N generation and activity. Direct inhibition of GSDMD-N pore formation (e.g., covalent modification of Cys191 by disulfiram blocks pore formation).